Intellia Therapeutics (NASDAQ:NTLA) EVP Edward Dulac III Sells 4,677 Shares

Intellia Therapeutics, Inc. (NASDAQ:NTLA) EVP Edward Dulac III sold 4,677 shares of the stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $18.00, for a total transaction of $84,186.00. Following the completion of the transaction, the executive vice president directly owned 156,286 shares in the company, valued at $2,813,148. The trade was a 2.91% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Intellia Therapeutics Stock Performance

Intellia Therapeutics stock opened at $17.38 on Tuesday. Intellia Therapeutics, Inc. has a fifty-two week low of $7.95 and a fifty-two week high of $28.25. The stock has a market cap of $2.43 billion, a P/E ratio of -4.91 and a beta of 1.77. The firm’s fifty day moving average price is $14.17 and its 200-day moving average price is $13.13.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.11. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. The company had revenue of $15.05 million during the quarter, compared to analyst estimates of $13.81 million. During the same period in the previous year, the business earned ($1.10) earnings per share. On average, analysts predict that Intellia Therapeutics, Inc. will post -3.18 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of Intellia Therapeutics in a research report on Monday, June 15th. Robert W. Baird upped their target price on Intellia Therapeutics from $7.00 to $13.00 and gave the stock a “neutral” rating in a research note on Monday, April 27th. New Street Research set a $25.00 price target on shares of Intellia Therapeutics in a research report on Monday, June 15th. Citigroup reissued a “market outperform” rating on shares of Intellia Therapeutics in a research note on Monday, June 15th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $49.00 price objective on shares of Intellia Therapeutics in a report on Tuesday, June 16th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $20.46.

Institutional Trading of Intellia Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. ARK Investment Management LLC boosted its position in Intellia Therapeutics by 19.2% during the 4th quarter. ARK Investment Management LLC now owns 14,207,324 shares of the company’s stock valued at $127,724,000 after buying an additional 2,288,146 shares during the period. Vanguard Group Inc. increased its position in shares of Intellia Therapeutics by 17.8% in the fourth quarter. Vanguard Group Inc. now owns 13,010,001 shares of the company’s stock valued at $116,960,000 after acquiring an additional 1,965,181 shares during the period. State Street Corp raised its stake in shares of Intellia Therapeutics by 29.1% during the fourth quarter. State Street Corp now owns 6,418,836 shares of the company’s stock valued at $57,705,000 after acquiring an additional 1,447,967 shares during the last quarter. Baker BROS. Advisors LP raised its stake in shares of Intellia Therapeutics by 2.7% during the third quarter. Baker BROS. Advisors LP now owns 2,746,674 shares of the company’s stock valued at $47,435,000 after acquiring an additional 71,000 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Intellia Therapeutics by 4.1% during the fourth quarter. Geode Capital Management LLC now owns 2,696,187 shares of the company’s stock worth $24,243,000 after purchasing an additional 107,333 shares during the period. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.